Conclusion
We present the first analysis on cost of the implantation of sutureless valves compared with standard aortic valve prostheses in the United States and have demonstrated acceptable short-term outcomes. These rapid deployment valves also facilitate the use of minimally invasive approaches and result in lower cardiopulmonary bypass and cross-clamp times, which may be beneficial in older patients and higher-risk multicomponent operations. We have also demonstrated cost neutrality, and the decreasing incidence of heart block over time likely due to changes in implantation technique. We feel this valve offers another tool for surgeons in an era of TAVR growth.